Hikma gets FDA approval for generic narcolepsy treatment
18th Jan 2017 09:29
(ShareCast News) - Hikma Pharmaceuticals' US subsidiary Roxane Laboratories has received approval from the US Food and Drug Administration for its sodium oxybate oral solution for the treatment of cataplexy - sudden loss of muscle strength - and excessive daytime sleepiness in patients with narcolep
Read moreFTSE 100 movers: Pharmaceutical stocks lead FTSE's rally
16th Dec 2016 14:11
(ShareCast News) - The FTSE 100 rose 0.11% to 7,006.73 points on Friday afternoon with pharmaceutical stocks leading the way. Hikma Pharmaceuticals, Shire and Astrazeneca rallied on a positive read-across following reports Sanofi is in advanced talks to acquire Actelion. The companies are said to b
Read moreLondon close: Miners propel FTSE 100 higher as industrial metals surge
22nd Nov 2016 16:34
(ShareCast News) - London equities ended Tuesday on a sharply higher note with major miners storming ahead in tandem with soaring industrial metals prices, and followed by a string of banks and insurers. US interest rate-touch utilities were firmly higher, too. FTSE 100 closed the session up 0.62%
Read moreHikma signs agreement with Vectura for salmeterol
22nd Nov 2016 07:18
(ShareCast News) - Hikma Pharmaceuticals has signed a development and licensing agreement with Vectura for its generic salmeterol product (VR730) for the treatment of asthma and chronic obstructive pulmonary disease. Under the terms of the agreement - which has been signed by Hikma's US affiliate, W
Read moreHikma gets shot in arm from Morgan Stanley upgrade
15th Nov 2016 11:38
(ShareCast News) - Hikma Pharmaceuticals got a shot in the arm on Tuesday as Morgan Stanley upped the stock to 'overweight' from 'equalweight' pointing to increased confidence in the pipeline and an attractive valuation. MS said its "deep dive" into Hikma's medium-term pipeline and long-term opportu
Read moreLondon close: Blue chips slide, led by gold-exposed miners amid profit-taking
10th Nov 2016 17:01
(ShareCast News) - London blue-chip stocks fell on Thursday as traders took profits stoked by Donald Trump's election win, with gold-exposed miners, pharmaceutical and US rates-sensitive utilities all flopping. The FTSE 100 ended the session down 1.21% to 6,827.98 points, somewhat out of kilter with
Read moreHikma Pharmaceuticals nudges down FY revenue guidance
10th Nov 2016 07:12
(ShareCast News) - Hikma Pharmaceuticals said on Thursday that it is currently generating "good" revenue growth, but it nudged down its full-year revenue guidance, saying it now expects it to rise by around 35% to $2bn at constant currency, down from a previous range of $2bn to $2.1bn. The injectabl
Read moreSector movers: Miners, US election-related plays lead gains
9th Nov 2016 15:17
(ShareCast News) - Steel and mining stocks led gains for another session, amid widespread gains for most base metals and coal, helped by an initial bout of weakness in the US dollar. As of 1650 GMT, the US dollar was trading higher by 0.47% to 98.32 points after having earlier hit an intra-day low a
Read moreBroker tips: Aggreko, Hikma, Croda
4th Nov 2016 13:25
(ShareCast News) - Morgan Stanley upgraded power generator company Aggreko from 'underweight' to 'equal weight' and bumped up its target price from 850p to 900p, despite orders for diesel products falling. "We retain our concerns over long-term pressures on the International power Projects (IPP) bus
Read moreNumis upgrades rating on Hikma Pharmaceutical but cuts target price
4th Nov 2016 10:12
(ShareCast News) - Numis on Friday upgraded its rating on Hikma Pharmaceutical to 'buy' from 'hold' but cut its target price to 2,350p from 2,660p. Hikma's shares have fallen 35% over the past three months and significantly underperformed UK Mid-Cap Healthcare and Global Specialty Pharma, Numis high
Read moreDirector dealings: Hikma trio building dominant stake
26th Sep 2016 15:42
(ShareCast News) - Hikma Pharmaceutical's founding family, led by including chairman and chief executive Said Darwazah, have spent another £6m buying shares in the drug maker in the last few days. Darwazah, his brother and vice chairman Mazen, and non-executive Ali Al-Hursy, who also has an equity s
Read moreMonday broker round-up
12th Sep 2016 09:24
(ShareCast News) - Autotrader: Barclays reiterates equal-weight with a target price of 375p. Hikma: Jefferies maintains buy with a 2500p target. Wood Group: Exane BNP Paribas upgrades to buy with a 815p target. Man Group: Citigroup upgrades to buy with a 137p target. McCarthy & Stone: Goldman Sac
Read moreDirector dealings: Hikma Pharma's founding family capitalise on share price slump
1st Sep 2016 15:25
(ShareCast News) - Three Hikma Pharmaceuticals directors, including chairman and chief executive Said Darwazah, took the opportunity to each snap up £3m worth of shares in the drugmaker as the stock slumped to its lowest level since early April. Darwazah and his brothers, vice chairman Mazen, sons o
Read moreDirectors dealings: Hikma's Said Darwazah buys £4.32m of shares
26th Aug 2016 17:48
(ShareCast News) - Hikma Pharmaceuticals chairman and chief executive Said Darwazah has splashed on £4.32m worth of the firm's shares, just a day after they dived on comments from US presidential hopeful Hillary Clinton. Darwazah, whose father founded the company, paid 2160p a share, snaffling 200,0
Read moreShire, AstraZeneca and Hikma hit by Hillary Clinton's pharma-bashing
25th Aug 2016 09:14
(ShareCast News) - Hikma Pharmaceuticals, Shire and AstraZeneca were among FTSE-listed drug companies slipping lower on Thursday morning, following comments from US presidential favourite Hillary Clinton on pharmaceutical pricing that hit peers across the Atlantic overnight. Clinton joined senators
Read more